Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Launched by MYLAN INC. · Mar 24, 2017

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject is a male or female subject 40 years of age or older with a diagnosis of COPD.
• • Subject has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack-years.
• • Subject is willing and able to provide signed and dated written informed consent to participate prior to initiation of any study related procedures.
• Exclusion Criteria:
• • Subject has a concurrent disease or condition that, in the opinion of the investigator, would interfere with continued study participation or confound the evaluation of safety and tolerability of the study drug.
• • Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergics.
• • Subject suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention.